Mr. David C. Pollack
Quotient Pharmaceuticals Manufacturing
Co-Founder, CEO, Chairman of the Board
David C. Pollack, Co-Founder, Chairman of the Board and CEO
Mr. Pollack is the son of Dr. William Pollack, the developer of RhoGAM and Hepatitis B Immune Globulin. David worked closely with his father on this project for more than 10 years and also provided millions in support for his father’s research. He helped co-develop the Company’s fractionation manufacturing process and much of the Company’s platform of technology. He spent years with his father focused on the key elements of immune control, product specification and production. With a significant base of immunological knowledge, Mr. Pollack led the development of a precise immunoglobulin fractionation process and produced the Streptococcus Pneumoniae human polyvalent antibody. He helped design and build the class 5 clean rooms and founded the Company. He has reviewed with the Quotient team thousands of technical papers and every element of the Company’s core technology, production and IP.
David is a financier and corporate executive with experience spanning a wide range of business activities, including corporate management, new technology commercialization, underwriting, and capital formation. He has a strong background in corporate, secured-debt, project-finance and the capital markets. David has raised over a billion dollars in capital across multiple business sectors including large industrial operations. He has experience in the funding and commercialization of technology and has been responsible for the issuance of over 350 patents worldwide.